Abstract
Background: Adjuvant and neoadjuvant therapies have been proposed to improve the prognosis of patients (pts) with stage II/IIIA lung cancer but have provided only modest survival benefits. When added to chemotherapy, PD-(L)1 inhibitors have resulted in enhanced antitumor activity versus chemotherapy alone, but their ability to limit relapse in pts who have undergone surgical resection has not yet been fully elucidated. Tislelizumab, a monoclonal antibody with high affinity and specificity for PD-1, was engineered to minimize binding to FcyR on macrophages to abrogate antibody-dependent phagocytosis.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
